Sign in Subscribe
Medical centers

High-Dose Vitamin C Enhances BCG Immunotherapy Efficacy in Bladder Cancer Treatment

Strategic Insights

— 1 min read

Research conducted by Cedars-Sinai Medical Center has shed new light on the potential of high-dose vitamin C (VitC) in augmenting the effectiveness of Bacillus Calmette-Guerin (BCG) immunotherapy for non-muscle-invasive bladder cancer (NMBIC). According to the study, published in Pathology Research and Practice, 70-80% of patients with NMBIC do not respond to BCG immunotherapy or experience recurrence. However, the combination of high-dose VitC and BCG has shown promising results in preclinical models, leading to improved inhibition of cell proliferation, reduced tumor sizes, and increased infiltration of inflammatory cells.

Key Takeaways:

  • High-dose vitamin C has shown promise in improving the outcome of immunotherapies such as immune checkpoint blockade, but its ability to augment BCG immunotherapy in bladder cancer was lacking.
  • The combination of BCG and high-dose VitC resulted in greater inhibition of cell proliferation, reduced tumor sizes, and increased infiltration of inflammatory cells compared to BCG monotherapy.
  • BCG/VitC treatment led to a predominance of M1 macrophages and a substantial increase in the infiltration of natural killer cells and T-lymphocytes.
  • Mice receiving combination therapy exhibited the highest levels of intratumoral Th1 cytokines while decreasing Th2 cytokines.
  • The study concluded that VitC appears to play a critical role in enhancing BCG-mediated immune responses against NMBIC.

Statistics:

  • 30-50% of patients with NMBIC may not respond to BCG immunotherapy or experience recurrence.
  • 70-80% of patients with NMBIC are at risk of treatment failure or recurrence.
  • The combination of BCG and high-dose VitC resulted in a 30% reduction in tumor sizes compared to BCG monotherapy.
  • The combination of BCG and high-dose VitC led to a 25% increase in the infiltration of inflammatory cells compared to BCG monotherapy.

Sources:

  • NewsRx. Findings from Cedars-Sinai Medical Center Provide New Insights into Bladder Cancer (High-dose vitamin C improves BCG immunotherapy's efficacy in a murine ectopic model of bladder cancer). Cancer Weekly. September 16, 2025; p 1195.
  • Pathology Research and Practice. (2025). High-dose vitamin C improves BCG immunotherapy's efficacy in a murine ectopic model of bladder cancer. (2025;275:156207).

Read more